# A Long-Term Extension Study for Participants With Treatment-resistant Major Depressive Disorder Who Are Continuing Esketamine Nasal Spray Treatment

> **NCT04829318** · PHASE4 · COMPLETED · sponsor: **Janssen-Cilag Ltd.** · enrollment: 183 (actual)

## Conditions studied

- Depressive Disorder, Major

## Interventions

- **DRUG:** Esketamine
- **DRUG:** SSRI/SNRI

## Key facts

- **NCT ID:** NCT04829318
- **Lead sponsor:** Janssen-Cilag Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-04-26
- **Primary completion:** 2024-07-22
- **Final completion:** 2024-07-22
- **Target enrollment:** 183 (ACTUAL)
- **Last updated:** 2025-09-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04829318

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04829318, "A Long-Term Extension Study for Participants With Treatment-resistant Major Depressive Disorder Who Are Continuing Esketamine Nasal Spray Treatment". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04829318. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*